Formulation Optimization of Solid Self-microemulsifying Pellets for Enhanced Oral Bioavailability of Curcumin
Overview
Pharmacy
Affiliations
Solidification of self-microemulsifying drug delivery systems (SMEDDS) is one of the major trends to promote the transformation of self-microemulsion technology into industrialization. Here, a preliminary curcumin SMEDDS formulation was constructed to improve the druggability of curcumin, through the determination of equilibrium solubility determination, self-emulsifying grading assessment, and pseudo-ternary phase diagrams drafting. Furthermore, the optimal curcumin SMEDDS formulation consisted of 10% Ethyl oleate, 57.82% Cremophor RH 40, and 32.18% Transcutol P was obtained by the simplex lattice design. Besides, curcumin solid self-microemulsifying drug delivery system (S-SMEDDS) was developed by the extrusion and spheronization process to achieve the solidification of SMEDDS. The formulation of curcumin S-SMEDDS pellets was screened by the single factor experiment and the process parameters were investigated using the orthogonal optimization method. Subsequently, curcumin S-SMEDDS pellets were evaluated by apparent morphology characterization, redispersibility study, drug release behavior, and pharmacokinetic evaluation. Results from the pharmacokinetic study in rabbits showed that the AUC of the curcumin S-SMEDDS pellets and curcumin suspension were 5.91 ± 0.28 µg/mL·h and 2.05 ± 0.04 µg/mL·h, while the relative bioavailability was 289.30%. These studies demonstrated that S-SMEDDS pellets can be a promising strategy for curcumin industrialized outputs.
Zhang Q, Ye X, Zhu L, Xu Z, Hou Y, Ke Q Front Pharmacol. 2024; 15:1456721.
PMID: 39415839 PMC: 11480027. DOI: 10.3389/fphar.2024.1456721.
Dong X, Thao Duyen Nguyen N Int J Pharm. 2024; 661:124447.
PMID: 39002820 PMC: 11571485. DOI: 10.1016/j.ijpharm.2024.124447.
Defining the mechanisms behind the hepatoprotective properties of curcumin.
Yashmi F, Fakhri S, Shiri Varnamkhasti B, Amin M, Khirehgesh M, Mohammadi-Noori E Arch Toxicol. 2024; 98(8):2331-2351.
PMID: 38837048 DOI: 10.1007/s00204-024-03758-7.
Ma T, Tang B, Wang Y, Shen M, Ping Y, Wang L Heliyon. 2023; 9(6):e17125.
PMID: 37416658 PMC: 10320271. DOI: 10.1016/j.heliyon.2023.e17125.
Sardou H, Vosough P, Abbaspour M, Akhgari A, Sathyapalan T, Sahebkar A Inflammopharmacology. 2023; 31(3):1095-1105.
PMID: 36757584 DOI: 10.1007/s10787-023-01140-0.